Last Posted: Jun 15, 2017
Polygenic Versus Monogenic Causes of Hypercholesterolemia Ascertained Clinically.
Wang Jian et al. Arteriosclerosis, thrombosis, and vascular biology 2016 Dec 36(12) 2439-2445
Greater preclinical atherosclerosis in treated monogenic familial hypercholesterolemia vs. polygenic hypercholesterolemia.
Sharifi Mahtab et al. Atherosclerosis 2017 May
When do paediatric patients with familial hypercholesterolemia need statin therapy?
Hennig Matylda et al. Developmental period medicine 2017 21(1) 43-50
How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
Masana Luis et al. Atherosclerosis 2017 May 262107-112
Recent advances in genetic testing for familial hypercholesterolemia.
Iacocca Michael A et al. Expert review of molecular diagnostics 2017 May
The rationale and design of the national familial hypercholesterolemia registries in Turkey: A-HIT1 and A-HIT2 studies.
Kayikçioglu Meral et al. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir 2017 Apr 45(3) 261-267
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.